GOVERNMENT OF INDIA
HEALTH AND FAMILY WELFARE
LOK SABHA

UNSTARRED QUESTION NO:2084
ANSWERED ON:28.07.2017
Research and Development in Pharma Sector
Patel Shri Prahlad Singh

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

Will the Minister of HEALTH AND FAMILY WELFARE be pleased to state:

(a) whether the Government is giving highest consideration to R&D in pharma sector;

(b) if so, the details thereof and if not, the reasons therefor;

(c) the budget allocated to the Central Drug Research Institute (CDRI) during the last three years and the current year;

(d) whether the Government is considering involvement of private sector for developing new drugs in order to fight acute diseases in the country;

(e) if so, the details thereof and if not, the reasons therefor; and

(f) the steps taken/ to be taken by the Government in this regard?

Answer

ANSWER
THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND
FAMILY WELFARE
(SHRI FAGGAN SINGH KULASTE)
(a) & (b): The Department of Science and Technology (DST) under Drugs and Pharmaceuticals Research Programme (DPRP), has been supporting R&D projects in modern Indian System of Medicines since 1994-95 as collaborative projects (public private partnership) and facility projects to academic institutions/national laboratories to cater to the needs of Indian Pharma Industries. During 2004-05, DST extended support to Indian Pharma industry for R&D projects in drug development. From 2008-09 onwards, this programme is extending grants-in-aid to Indian pharmaceutical industries for clinical trials for neglected diseases such as Tuberculosis, Malaria, Kala-Azar, Filariasis, etc. The major objectives of the programme are:
â€¢ To synergise the strengths of publicly funded R&D institutions and Indian Pharmaceutical Industry;

Contdâ€¦â€¦..

-2-

â€¢ To create an enabling infrastructure, mechanisms and linkages to facilitate new drug development;
â€¢ To stimulate skill development of human resources in R&D for drugs and pharmaceuticals; and
â€¢ To extend soft loan for Pharma industrial R&D projects.

In addition to the above, Council of Scientific & Industrial Research (CSIR) has been pursuing R&D activities in the domain of drugs and pharmaceuticals with the emphasis on affordable healthcare. Further, Indian Council of Medical Research (ICMR) has been supporting research (in the area of pharma sector) through extramural research as adhoc projects, fellowship projects, Task Force projects and has established Centres of Advanced Research in Pre-clinical & Clinical Pharmacology with a view to setting up National facilities for the development of New Chemical entities.
(c): Budget allocated to CDRI, Lucknow during the last three years and the current year is as below:

Financial Year	2014-15	2015-16	2016-17	2017-18*
Allocation (Rs in crore)	179.789	179.130	160.497	66.788

*Allocation till date

(d) to (f): As detailed in (a) & (b) above, DPRP focuses on collaboration projects including Public Private Partnership (PPP).
â€¦â€¦â€¦â€¦â€¦â€¦